SAN FRANCISCO — In a new phase 1b trial, KSI-301, an antibody biopolymer conjugate that blocks VEGF isoforms, demonstrated strong durability and safety for the treatment of wet age-related macular degeneration, as well as diabetic macular edema and retinal vein occlusion, according to a speaker at the American Academy of Ophthalmology annual meeting.
“One of the biggest challenges in retina right now is the durability of our anti-VEGF agents,” Charles C. Wykoff, MD, PhD, told Ocular Surgery News. “They work extremely well, and many patients have done very well with
Uncategorized